Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study

What Was Tested

The paper reports a study of Teriparatide, published as a observational study.

Who Took Part

According to the abstract, 323 patients were involved.

By PubMed's age tags, the people studied were older adults and people over 80, women only.

In this retrospective, case-controlled, multicenter study, 323 postmenopausal patients were initiated ROMO.

Of these, 275 were treatment-naïve, and 48 were switched from TPTD, with uninterrupted ROMO treatment for 12 months.

How the Study Was Run

The researchers set it up as a multicenter study.

More than one site took part, so the patients came from several places.

The methods mention a period of 12 months.

Propensity score matching was applied to ensure clinical comparability, yielding 44 patients in each group.

Baseline characteristics included a mean age of 78.0 years, lumbar spine (LS) T-score of -3.6, and total hip (TH) T-score of -2.8.

Bone mineral density (BMD) and serum bone turnover markers were evaluated over the 12-month period.

What Was Measured

The subject headings attached to it are Antibodies, Monoclonal, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Case-Control Studies and Osteoporosis, Postmenopausal.

The authors tagged it with the keywords Bone formation, Bone mineral density, Postmenopausal osteoporosis, Romosozumab and Teriparatide.

What This Means in Plain Language

The paper is a multicenter study of Teriparatide in 323 patients over 12 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Bone), a journal based in United States.

More context: the Teriparatide compound page, all human trials.